Pamplona

• An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1) Pending
  2025-522944-41-00 7 Solid Tumours
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS Pending
  2025-523396-38-00 9 Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r high
• A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Pending
  2025-523474-16-00 7 Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mu
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Pending
  2025-523495-23-00 5 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• A Basket Trial of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies Pending
  2025-523774-16-00 9 Advanced malignancies
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) Pending
  2025-524181-26-00 4 relapsed/refractory multiple myeloma
• Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending
  2025-525068-13-00 4 Chronic Kidney Disease
• Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting
  2025-522107-18-00 4 2026-05-19 Locally advanced or metastatic Non-Small Cell Lung Cancer
• INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS Recruiting
  2024-515009-24-00 4 2026-05-08 High grade malignant brain neoplasm
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• Efficacy and safety study of intravenous brincidofovir compared to intravenous cidofovir for the treatment of adenovirus infection in childr … Recruiting
  2025-521903-28-00 5 2026-05-06 Adenovirus viremia
• A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting
  2025-522867-13-00 4 2026-04-27 Non Small Cell Lung Cancer
• A study to assess the effects of zigakibart on IgA nephropathy. Recruiting
  2024-519699-24-00 4 2026-04-23 IgA nephropathy
• A study for adolescents who are depressed and thinking of suicide Recruiting
  2024-518615-19-00 5 2026-04-22 Major Depressive Disorder
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• Darovasertib before Surgery or Radiation Therapy to Treat Early-stage Eye Cancer (Uveal Melanoma) Recruiting
  2025-522387-32-00 5 2026-04-10 Uveal Melanoma
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting
  2024-519555-28-00 5 2026-03-18 Dravet syndrome

Showing 49–72 of 821 trials